Notably, while these findings establish POSTN as a biomarker of advanced fibrotic deterioration, current clinical evidence remains insufficient to validate its direct cardioprotective potential against hypertension-induced myocardial injury. This evidence concerns the gene POSTN and hypertensive disorder.